carvedilol has been researched along with Experimental Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoare, JI | 1 |
| Osmani, B | 1 |
| O'Sullivan, EA | 1 |
| Browne, A | 1 |
| Campbell, N | 1 |
| Metcalf, S | 1 |
| Nicolini, F | 1 |
| Saxena, J | 1 |
| Martin, SA | 1 |
| Lockley, M | 1 |
| Carvalho Rodrigues, MA | 1 |
| Silva Faria, MC | 1 |
| Santos, NA | 1 |
| Gobe, GC | 1 |
| dos Santos, AC | 1 |
2 other studies available for carvedilol and Experimental Neoplasms
| Article | Year |
|---|---|
Carvedilol targets β-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy.
Topics: Adenoviridae; Adrenergic alpha-1 Receptor Antagonists; Animals; beta-Arrestins; Carvedilol; Cell Lin | 2022 |
Carvedilol efficiently protects kidneys without affecting the antitumor efficacy of cisplatin in mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carbazoles; Carvedilol; Cisplatin; Dose-Response Relation | 2013 |